Sanofi SA

Sanofi’s conditional approval of Rezurock (nintedanib) for cGVHD offers a high‑value niche therapy, but its future hinges on a 12‑18‑month confirmatory trial and reimbursement timelines.

Sanofi’s dual pipeline—Amlitelimab for atopic dermatitis and Sarclisa sub‑cutaneous injector for multiple myeloma—offers cost‑effective, home‑care delivery, promising higher margins and stronger payer appeal.

Sanofi’s phase‑three amlitelimab data reveal a promising biologic for atopic dermatitis with lower dosing, strong patent protection, and solid revenue potential, but success hinges on strategic pricing, payer wins, and timely M&A moves.

Sanofi secures new Japan approval for Dupixent in bullous pemphigoid, expanding its biologic portfolio, while revealing detailed Q1 2026 financial guidance to boost investor confidence.

Sanofi’s March 2026 update reveals orphan status for rilzabrutinib in Japan, new EU approval for Dupixent in children with chronic urticaria, and solid efficacy data for Ayvakit in mastocytosis, underscoring the company’s expanding reach in rare dis…

Sanofi’s latest regulatory wins—Japan orphan status for rilzabrutinib, EMA approval of Acoziborole, and EU recommendation for Dupixent CSU—show how a balanced portfolio of blockbuster, niche, and public‑health products can boost revenue and diversif…

Sanofi’s FDA approval of Dupixent for allergic fungal rhinosinusitis shows the drug’s IL‑4/IL‑13 blockade reduces nasal symptoms, steroid use and surgery—boosting its portfolio and investor confidence.

Sanofi SA’s strategy to navigate patent cliffs, market‑access challenges and growth opportunities, from biosimilars to targeted M&A, reveals how the pharma giant keeps revenue rising and staying ahead of competition.

Sanofi’s LTE data show duvakitug achieves 78 % remission in UC and 73 % in CD with acceptable safety, while new SCBU leadership aims to boost specialty growth and R&D investment.

Sanofi’s Phase 2b duvakitug data boost IBD prospects, a Hyderabad GCC expansion cuts costs, and new RSV vaccine Beyfortus targets a $2.8 billion market. Click to see how these moves could generate $1.1 billion annual revenue.